Peter Bulova

Morbidity and medication in a large population of individuals with Down syndrome compared to the general population

The Down syndrome brain in the presence and absence of fibrillar β-amyloidosis

Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome

A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome

Searching for new pharmacological targets for the treatment of Alzheimer's disease in Down syndrome

Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease

Dementia in Down syndrome: unique insights for Alzheimer disease research

A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome

Dementia in Down's syndrome

Down syndrome

Down Syndrome

The neuropathological diagnosis of Alzheimer’s disease

Alzheimer's disease in Down syndrome: An overlooked population for prevention trials

The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease

Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer’s Disease: The Role of APP

Leisure Activity and Caregiver Involvement in Middle-Aged and Older Adults With Down Syndrome

Co‐occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines

Managing the care of adults with Down's syndrome

Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome

Co‐occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines. Part II

The effects of normal aging on amyloid‐β deposition in nondemented adults with Down syndrome as imaged by carbon 11–labeled Pittsburgh compound B

Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B

Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome

Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population